[HTML] sciencedirect.com

[HTML][HTML] Initial results from a phase 1 clinical study of bb21217, a next-generation anti Bcma CAR T therapy

N Shah, M Alsina, DS Siegel, S Jagannath, D Madduri… - Blood, 2018 - Elsevier
Introduction: Immunomodulatory chimeric antigen receptor (CAR) T cell therapy directed
against B-cell maturation antigen (BCMA) has shown promising results for the treatment of …
被引用次数：81 相关文章

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

N Shah, M Alsina, DS Siegel, S Jagannath, D Madduri… - 2018 - ashpublications.org
Introduction: Immunomodulatory chimeric antigen receptor (CAR) T cell therapy directed
against B-cell maturation antigen (BCMA) has shown promising results for the treatment of …

Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy

N Shah, M Alsina, DS Siegel, S Jagannath, D Madduri… - 2018 - ashpublications.org
Introduction: Immunomodulatory chimeric antigen receptor (CAR) T cell therapy directed
against B-cell maturation antigen (BCMA) has shown promising results for the treatment of …